Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults

The purpose of our study was to examine the effect of immunomodulators (broncho-vaxom, immunovac-VP4 vaccine and polyoxidonium) upon the kinetics of serum hydrolase inhibitors and lactoferrin in the treatment of community-acquired pneumonia (CAP). The study included 71 CAP patients at th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. P. Kostinov, N. A. Zorin, S. V. Kazharova, V. N. Zorina
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2020
Materias:	immunomodulators hydrolase inhibitors lactoferrin community-acquired pneumonia Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/294685c1aea44582a31614178d709a83
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:294685c1aea44582a31614178d709a83
record_format	dspace
spelling	oai:doaj.org-article:294685c1aea44582a31614178d709a832021-11-18T08:03:50ZComparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults1563-06252313-741X10.15789/1563-0625-CEO-1548https://doaj.org/article/294685c1aea44582a31614178d709a832020-08-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1548https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe purpose of our study was to examine the effect of immunomodulators (broncho-vaxom, immunovac-VP4 vaccine and polyoxidonium) upon the kinetics of serum hydrolase inhibitors and lactoferrin in the treatment of community-acquired pneumonia (CAP). The study included 71 CAP patients at the age of 18 to 70 years. The patients were divided into 4 groups: Group I (15 people) was a control group treated with basic antibacterial and symptomatic therapy, according to the standard treatment regimen, without use of immunomodulators; the patients from group II (19 patients) were additionally administered bronchovaxom (the drug was prescribed upon admission: 1 course over 30 days, then 2 rounds for 10 days each, with an interval in 20 days); group III (20 cases) contained the patients who additionally received polyoxidonium (the drug was prescribed from the 1st day of hospitalization, 6 mg daily i/m for 3 days, then 10 injections over 10 days); group IV (17 cases): Immunovac-VP4 vaccine was administered orally 4 ml and intranasally 2 drops on days 1, 4, 7, 10, 13, 19, 25, 31, along with antibacterial and symptomatic therapy. This vaccine consists of antigens from opportunistic microorganisms (a multicomponent mixture of water-soluble antigens of S. aureus, K. pneumoniae, P. vulgaris, E. coli). Serum concentrations of α2-macroglobulin and α1-antitrypsin hydrolase inhibitors were determined by the method of quantitative immunoelectrophoresis using the research test systems; lactoferrin (LF) levels were evaluated by enzyme-linked immunosorbent assay using commercial test systems. These indicators were studied in blood serum before treatment, on the 2nd, 13th, and 60th days of observation. It was shown that administration of immune modulators combined with antibiotic therapy in patients with CAP can affect the kinetics of acute phase inflammatory proteins. The effect of broncho-vaxom corresponds to the classical pathway of the response to inflammatory process, i.e., activation of complex of positive acute phase reactants (α1-antitrypsin and lactoferrin) and inhibition (blocking) of negative acute phase reactants (α2macroglobulin). Polyoxidonium has a noticeable effect only upon neutrophils secreting lactoferrin. ImmunovacVP4 promotes only short-term secretion of this protein. One may assume that activation of hydrolase inhibitors and lactoferrin after use of immunotropic drugs enhances clinical effect of therapy, with decreased severity and duration of symptoms, as well as lower exacerbation risk of chronic diseases and lesser volume of drug intake. Antibacterial therapy does not significantly affect the kinetics of acute phase inflammation reactants in patients with CAP. Administration of immunomodulators in combination with standard basic therapy may affects the inflammatory process to different degree, thus, in turn, leading to improved prognosis in this disease.M. P. KostinovN. A. ZorinS. V. KazharovaV. N. ZorinaSPb RAACIarticleimmunomodulatorshydrolase inhibitorslactoferrincommunity-acquired pneumoniaImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 22, Iss 4, Pp 791-798 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	immunomodulators hydrolase inhibitors lactoferrin community-acquired pneumonia Immunologic diseases. Allergy RC581-607
spellingShingle	immunomodulators hydrolase inhibitors lactoferrin community-acquired pneumonia Immunologic diseases. Allergy RC581-607 M. P. Kostinov N. A. Zorin S. V. Kazharova V. N. Zorina Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
description	The purpose of our study was to examine the effect of immunomodulators (broncho-vaxom, immunovac-VP4 vaccine and polyoxidonium) upon the kinetics of serum hydrolase inhibitors and lactoferrin in the treatment of community-acquired pneumonia (CAP). The study included 71 CAP patients at the age of 18 to 70 years. The patients were divided into 4 groups: Group I (15 people) was a control group treated with basic antibacterial and symptomatic therapy, according to the standard treatment regimen, without use of immunomodulators; the patients from group II (19 patients) were additionally administered bronchovaxom (the drug was prescribed upon admission: 1 course over 30 days, then 2 rounds for 10 days each, with an interval in 20 days); group III (20 cases) contained the patients who additionally received polyoxidonium (the drug was prescribed from the 1st day of hospitalization, 6 mg daily i/m for 3 days, then 10 injections over 10 days); group IV (17 cases): Immunovac-VP4 vaccine was administered orally 4 ml and intranasally 2 drops on days 1, 4, 7, 10, 13, 19, 25, 31, along with antibacterial and symptomatic therapy. This vaccine consists of antigens from opportunistic microorganisms (a multicomponent mixture of water-soluble antigens of S. aureus, K. pneumoniae, P. vulgaris, E. coli). Serum concentrations of α2-macroglobulin and α1-antitrypsin hydrolase inhibitors were determined by the method of quantitative immunoelectrophoresis using the research test systems; lactoferrin (LF) levels were evaluated by enzyme-linked immunosorbent assay using commercial test systems. These indicators were studied in blood serum before treatment, on the 2nd, 13th, and 60th days of observation. It was shown that administration of immune modulators combined with antibiotic therapy in patients with CAP can affect the kinetics of acute phase inflammatory proteins. The effect of broncho-vaxom corresponds to the classical pathway of the response to inflammatory process, i.e., activation of complex of positive acute phase reactants (α1-antitrypsin and lactoferrin) and inhibition (blocking) of negative acute phase reactants (α2macroglobulin). Polyoxidonium has a noticeable effect only upon neutrophils secreting lactoferrin. ImmunovacVP4 promotes only short-term secretion of this protein. One may assume that activation of hydrolase inhibitors and lactoferrin after use of immunotropic drugs enhances clinical effect of therapy, with decreased severity and duration of symptoms, as well as lower exacerbation risk of chronic diseases and lesser volume of drug intake. Antibacterial therapy does not significantly affect the kinetics of acute phase inflammation reactants in patients with CAP. Administration of immunomodulators in combination with standard basic therapy may affects the inflammatory process to different degree, thus, in turn, leading to improved prognosis in this disease.
format	article
author	M. P. Kostinov N. A. Zorin S. V. Kazharova V. N. Zorina
author_facet	M. P. Kostinov N. A. Zorin S. V. Kazharova V. N. Zorina
author_sort	M. P. Kostinov
title	Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
title_short	Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
title_full	Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
title_fullStr	Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
title_full_unstemmed	Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
title_sort	comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults
publisher	SPb RAACI
publishDate	2020
url	https://doaj.org/article/294685c1aea44582a31614178d709a83
work_keys_str_mv	AT mpkostinov comparativeeffectofimmunomodulatorsonthecontentsofhydrolaseinhibitorsandlactoferrinincommunityacquiredpneumoniainadults AT nazorin comparativeeffectofimmunomodulatorsonthecontentsofhydrolaseinhibitorsandlactoferrinincommunityacquiredpneumoniainadults AT svkazharova comparativeeffectofimmunomodulatorsonthecontentsofhydrolaseinhibitorsandlactoferrinincommunityacquiredpneumoniainadults AT vnzorina comparativeeffectofimmunomodulatorsonthecontentsofhydrolaseinhibitorsandlactoferrinincommunityacquiredpneumoniainadults
_version_	1718422275949068288

Comparative effect of immunomodulators on the contents of hydrolase inhibitors and lactoferrin in community-acquired pneumonia in adults

Ejemplares similares